DZ Bank analyst Peter Spengler carried out a thorough analysis of the Merck paper.
DZ Bank left the classification for Merck KGAA on “Buy” with a fair price target of 151 euros per share. The life science market has a high organic growth potential, Peter Spengler wrote in an assessment on Monday. There would still be up to 17 billion euros available for acquisitions, also in the area of life science. The pharmaceutical portfolio is well reinforced by taking on jumpingworks. Merck is a company of high quality.
Stock assessment in detail: the Merck share and its development on the day of the analysis
The Merck share noted in green in Xetra trading at 12:05 p.m. and won 1.4 percent to EUR 114.20. Finally, the trading volume rose to 76,215 Merck shares via Xetra. The share has been a minus of 16.9 percent since the beginning of 2025.
Frankfurt (dpa-afx analysis) / editorial finance.net
Publication of the original study: 28.07.2025 / 10:06 / MESZ for the first time passing on of the original study: 28.07.2025 / 11:09 / MESZ
Note: Information on the obligation to disclose the disclosure for conflicts of interest within the meaning of Section 85 (1) WPHG, Art. 20 VO (EU) 596/2014 For the Analysten House mentioned can be found at http://web.dpa-afx.de/offengegungs-
Selected leverage products on Merck
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired lever and we will show you suitable open-end products on Merck
The lever must be between 2 and 20
Advertising